HELP$8.683.88%-0.35
After Hours: 8.60-0.08 -0.92%
Helus Pharma Inc (HELP)
Date: 2026-11-04 16:00O: 9.03H: 9.33L: 8.56C: 8.68Vol: 1.233M
Helus Pharma Inc stock is traded at $8.68, with a volume of 1,232,997. It is down -3.88% in the last 24 hours and down -25.81% over the past month. Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
Previous Close:
$9.03
Open:
$9.03
24h Volume:
1,232,997
Relative Volume:
0.80
Market Cap:
$634.24M
Revenue:
-
Net Income/Loss:
-$148.00M
P/E Ratio:
-
EPS:
-$4.43
Net Cash Flow:
-$135.66M
1W Performance:
-20.44%
1M Performance:
-25.81%
6M Performance:
+64.08%
1Y Performance:
0.00%
1-Day Range:
$8.56$9.33
1-Week Range:
$8.32$11.30
52-Week Range:
$3.76$15.15
Helus Pharma Inc Stock (HELP) Company Profile
Market Cap
Revenue
Net Income
Cash Flow
EPS
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
Helus Pharma Inc Stock (HELP) Financials Data
There is no financial data for Helus Pharma Inc (HELP). Check out other stocks for more information.
Helus Pharma Inc Stock (HELP) Insider Trading
- Cavers GregSep 29 '26Chief Financial Officer
- Transaction
- Buy
- Cost
- $12.91
- #Shares
- 3,000
- Value ($)
- 38,730
- #Shares Total
- 3,000
- Halstead MichaelSep 21 '26Chief Executive Officer
- Transaction
- Buy
- Cost
- $13.47
- #Shares
- 100,000
- Value ($)
- 1,347,050
- #Shares Total
- 168,568
- So Eric H. L.Sep 08 '26Executive Chair
- Transaction
- Buy
- Cost
- $12.39
- #Shares
- 100,000
- Value ($)
- 1,238,670
- #Shares Total
- 4,465,014
- Glavine PaulSep 08 '26Chief Growth Officer
- Transaction
- Buy
- Cost
- $12.47
- #Shares
- 100,000
- Value ($)
- 1,247,190
- #Shares Total
- 4,271,252
- Glavine PaulSep 08 '26Chief Growth Officer
- Transaction
- Buy
- Cost
- $12.47
- #Shares
- 100,000
- Value ($)
- 1,247,190
- #Shares Total
- 4,271,252
- So Eric H. L.Sep 04 '26Executive Chair
- Transaction
- Buy
- Cost
- $12.09
- #Shares
- 100,000
- Value ($)
- 1,208,900
- #Shares Total
- 4,365,014
- Glavine PaulSep 03 '26Chief Growth Officer
- Transaction
- Buy
- Cost
- $11.78
- #Shares
- 100,000
- Value ($)
- 1,178,280
- #Shares Total
- 4,171,252
- So Eric H. L.Sep 01 '26Executive Chair
- Transaction
- Buy
- Cost
- $11.80
- #Shares
- 95,000
- Value ($)
- 1,121,475
- #Shares Total
- 4,265,014
- Glavine PaulAug 31 '26Chief Growth Officer
- Transaction
- Buy
- Cost
- $11.59
- #Shares
- 90,000
- Value ($)
- 1,042,677
- #Shares Total
- 4,071,252
